Retreatment with trastuzumab in Her2-positive metastatic breast cancer patients: a clinical study
| Data(s) |
05/03/2013
05/03/2013
19/06/2007
|
|---|---|
| Resumo |
Objective: To study the benefit of trastuzumab in monotherapy or combined with different chemotherapeutic agents in the treatment for Her2+ metastatic breast cancer (MBC) patients after progression on prior trastuzumab therapy. |
| Identificador |
Carabante-Ocón F, Saez-Lara E, Burgos-Garcia L, Villar-Chamorro E, Casaus-Hazañas A. Luna S, et al. Retreatment with trastuzumab in Her2-positive metastatic breast cancer patients: a clinical study. Breast Cancer Research. 2007 Jun;9 Supplement 1:s17-8 1465-5411 (Print) 1465-542X (Online) http://hdl.handle.net/10668/804 10.1186/bcr1708 |
| Idioma(s) |
en |
| Publicador |
BioMed Central |
| Relação |
Breast Cancer Research http://breast-cancer-research.com/supplements/9/S1/all VII Madrid Breast Cancer Conference: Changes in the treatment of breast cancer 20-22 June 2007 Madrid, Spain. |
| Direitos |
Acceso abierto |
| Palavras-Chave | #trastuzumab #her2-positive #chemotherapies #MBC #neoplasias de la mama #Retratamiento #Medical Subject Headings::Diseases::Neoplasms::Neoplasms by Site::Breast Neoplasms #Medical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Retreatment |
| Tipo |
info:eu-repo/semantics/conferenceObject info:eu-repo/semantics/published Póster |
